# Riociguat

Drug · id `cardio:riociguat` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: ADEMPAS

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Riociguat, sold as Adempas, is a soluble guanylate cyclase stimulator. The US label lists two uses in adults: persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment, or inoperable disease, and pulmonary arterial hypertension (WHO Group 1), in both to improve exercise capacity. The label carries a boxed warning for embryo-fetal toxicity: it says the medicine is contraindicated during pregnancy because it may cause fetal harm. That risk concerns the unborn child and is recorded separately.

## Technical summary

RxNorm ingredient 1439816; UNII RU3FE2Y4XI. MeSH has no descriptor for riociguat (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Soluble Guanylate Cyclase Stimulator, so the record is filed under the class page. The label read is the Bayer HealthCare Pharmaceuticals Inc. label for Adempas, application NDA204819 (approved 2013-10-08 as a new molecular entity in Drugs@FDA), effective 2026-08-13 in openFDA. Chronic thromboembolic pulmonary hypertension has no page of its own in the atlas, so that indication links to the pulmonary hypertension page. The adult indications and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records label indications, the boxed-warning title and one sentence, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: The developing fetus, for a person taking riociguat during pregnancy, as described in a US label boxed warning

Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Adempas carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm, based on animal data.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:35Z. Source state: Current. Version fingerprint: 4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f.
     How it applies: Application number of the label read, NDA204819.
  2. Background: openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:35Z. Source state: Current. Version fingerprint: 4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f.
     How it applies: Effective date of the label text read, 20260813.
  3. Supports: openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-18T22:01:35Z. Source state: Current. Version fingerprint: 4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f.
     How it applies: Label passage quoted in the research quote table (Q-K29-ADE-LB-07).
  4. Supports: openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first paragraph. Retrieved 2026-11-18T22:01:35Z. Source state: Current. Version fingerprint: 4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f.
     How it applies: Label passage quoted in the research quote table (Q-K29-ADE-LB-08).

## Context: Adults with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension, as described in the US label of Adempas

Recipient: Adult; Population: Adults with persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment, or inoperable disease (WHO Group 4), and adults with pulmonary arterial hypertension (WHO Group 1), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Adempas (riociguat tablets, Bayer HealthCare Pharmaceuticals Inc., application NDA204819; the version dated 2026-08-13 in openFDA) describes riociguat as a soluble guanylate cyclase stimulator. It lists treating adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment, or inoperable disease, and adults with pulmonary arterial hypertension (WHO Group 1), to improve exercise capacity.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment, or inoperable disease (WHO Group 4), and adults with pulmonary arterial hypertension (WHO Group 1), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists improving WHO functional class and delaying clinical worsening; only the exercise capacity wording is quoted here.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:35Z. Source state: Current. Version fingerprint: 4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f.
     How it applies: Application number of the label read, NDA204819.
  2. Background: openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:35Z. Source state: Current. Version fingerprint: 4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f.
     How it applies: Effective date of the label text read, 20260813.
  3. Supports: openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:35Z. Source state: Current. Version fingerprint: 4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f.
     How it applies: Label passage quoted in the research quote table (Q-K29-ADE-LB-04, Q-K29-ADE-LB-05, Q-K29-ADE-LB-06).

## Connected pages

- Riociguat is a soluble guanylate cyclase stimulator (FDA established pharmacologic class in RxClass): Soluble guanylate cyclase stimulators (`cardio:soluble-guanylate-cyclase-stimulators`)
- FDA label lists pulmonary arterial hypertension (WHO Group 1) in adults, to improve exercise capacity, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-adempas-label-indications` and its context]
- FDA label lists persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) in adults, after surgical treatment or when inoperable, as an indication: Pulmonary hypertension (`cardio:pulmonary-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-adempas-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 33a4b24de03dc32a1de996a643b59b869214ae1059dae7ca7fcba6a991ba92e4
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
